कंपनी का अवलोकन
Nano-X Imaging Ltd. is a healthcare entity focused on the medical devices sector, specifically engineering commercial-grade tomographic imaging devices that utilize digital X-ray sources alongside teleradiology services and artificial intelligence applications for real-world medical use. The company operates within the specialized medical device industry, aiming to provide advanced imaging solutions through its Nanox Multi Source System and related technologies. At present, the organization employs approximately 165 staff members and maintains a total market capitalization of $167.71 million. Its trailing twelve-month revenue stands at $12.30 million, which, when combined with its market cap, indicates a valuation multiple that is significantly higher than its current sales output. This disparity suggests that the market is pricing the company based on future growth potential and technological moats rather than current profitability, placing it in the early-to-mid growth phase typical of capital-intensive medical technology firms.
वित्तीय स्वास्थ्य
The company reported a revenue of $12.30 million over the trailing twelve months, yet it recorded a net income loss of $55.706 million, revealing a substantial gap where operating expenses far exceed gross revenue generation. The EBITDA for the period was a negative $45.925 million, indicating that even before interest and taxes, the core business operations are currently burning cash. Free cash flow stands at a negative $26.87775 million, which signifies a heavy reliance on external capital injections or cash reserves to fund operations and research and development rather than organic cash generation. The gross margin is negative 98.0%, while the operating margin is negative 413.0%, and the profit margin is 0.0%, all of which reflect a cost structure where fixed costs, likely related to R&D and manufacturing setup, outweigh current sales volume. On the balance sheet, the company holds $45.19 million in cash against $7.88 million in debt, resulting in a debt-to-equity ratio of 5.03, which suggests a highly leveraged position relative to equity but provides a strong liquidity buffer due to the cash hoard. The current ratio is 4.14, indicating that the company has more than four times the current assets needed to cover its short-term liabilities, pointing to robust short-term liquidity despite the operational losses. Return on equity is negative 34.8% and return on assets is negative 20.0%, metrics that reveal management is currently utilizing shareholder and asset bases to generate negative returns, a common scenario for growth-stage biotech or medtech firms but one that warrants monitoring for eventual profitability.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is calculated at -7.90, implying that expected future earnings are currently projected to remain negative or that the market is pricing in significant recovery time before positive earnings materialize. The price-to-book ratio stands at 1.01, indicating that the market values the company at essentially one dollar for every dollar of its book value, suggesting the market does not currently assign a significant premium to the company's intangible assets or future growth prospects over its tangible book equity. The price-to-sales ratio is 13.63, and the EV/EBITDA is -2.62, both of which are alternative valuation metrics that suggest the company is trading at a premium relative to its sales but at a negative multiple relative to earnings, highlighting the speculative nature of the valuation. The stock has traded between a 52-week high of $5.86 and a 52-week low of $2.11; depending on the current share price, the stock sits within this volatility range, reflecting high investor sentiment swings typical for small-cap healthcare stocks. The beta value is 1.38, which means the stock is expected to be 38% more volatile than the broader market, indicating higher risk and potential for sharper price movements during market corrections or rallies.
Growth & Income
Nano-X Imaging Ltd. has demonstrated revenue growth of 13.7% year-over-year, while earnings growth is N/A due to the company's continued net losses, implying that revenue expansion is occurring without a corresponding improvement in profitability yet. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the organization reinvests all available capital and earnings retention into its operations, research, and product development rather than distributing income to shareholders. The absence of a dividend policy aligns with the company's stage of development, where preserving cash reserves is critical to sustaining operations until the imaging devices and AI applications achieve commercial scale. The overall growth and income profile is characterized by strong revenue expansion coupled with significant cash burn and no current income distribution, positioning the company as a pure growth play dependent on future operational success.